467 related articles for article (PubMed ID: 24038200)
1. The utility of PSA velocity in prediction of prostate cancer and high grade cancer after an initially negative prostate biopsy.
Elshafei A; Li YH; Hatem A; Moussa AS; Ethan V; Krishnan N; Li J; Jones JS
Prostate; 2013 Dec; 73(16):1796-802. PubMed ID: 24038200
[TBL] [Abstract][Full Text] [Related]
2. Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy.
Spurgeon SE; Mongoue-Tchokote S; Collins L; Priest R; Hsieh YC; Peters LM; Beer TM; Mori M; Garzotto M
Urology; 2007 May; 69(5):931-5. PubMed ID: 17482937
[TBL] [Abstract][Full Text] [Related]
3. PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy.
Elshafei A; Chevli KK; Moussa AS; Kara O; Chueh SC; Walter P; Hatem A; Gao T; Jones JS; Duff M
Prostate; 2015 Dec; 75(16):1951-7. PubMed ID: 26384170
[TBL] [Abstract][Full Text] [Related]
4. Prostate specific antigen velocity per prostate volume: a novel tool for prostate biopsy prediction.
Choi SY; Chang IH; Kim YS; Kim TH; Kim W; Myung SC
Urology; 2011 Oct; 78(4):874-9. PubMed ID: 21791361
[TBL] [Abstract][Full Text] [Related]
5. Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
Wolters T; Roobol MJ; Bangma CH; Schröder FH
Eur Urol; 2009 Feb; 55(2):385-92. PubMed ID: 18353529
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
7. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
8. High detection rate of significant prostate tumours in anterior zones using transperineal ultrasound-guided template saturation biopsy.
Mabjeesh NJ; Lidawi G; Chen J; German L; Matzkin H
BJU Int; 2012 Oct; 110(7):993-7. PubMed ID: 22394668
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time.
Ng MK; Van As N; Thomas K; Woode-Amissah R; Horwich A; Huddart R; Khoo V; Thompson A; Dearnaley D; Parker C
BJU Int; 2009 Apr; 103(7):872-6. PubMed ID: 18990146
[TBL] [Abstract][Full Text] [Related]
10. Atypical small acinar proliferation (ASAP): Is a repeat biopsy necessary ASAP? A multi-institutional review.
Leone A; Gershman B; Rotker K; Butler C; Fantasia J; Miller A; Afiadata A; Amin A; Zhou A; Jiang Z; Sebo T; Mega A; Schiff S; Pareek G; Golijanin D; Yates J; Karnes RJ; Renzulli J
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):68-71. PubMed ID: 26857145
[TBL] [Abstract][Full Text] [Related]
11. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
[TBL] [Abstract][Full Text] [Related]
12. The combination of prostate imaging reporting and data system version 2 (PI-RADS v2) and periprostatic fat thickness on multi-parametric MRI to predict the presence of prostate cancer.
Cao Y; Cao M; Chen Y; Yu W; Fan Y; Liu Q; Gao G; Zhao Z; Wang X; Jin J
Oncotarget; 2017 Jul; 8(27):44040-44049. PubMed ID: 28476042
[TBL] [Abstract][Full Text] [Related]
13. Simple Risk Stratification to Detect Prostate Cancer with High Gleason Score in Repeat Biopsies in a Population Screening Follow-up Study.
Kitagawa Y; Urata S; Mizokami A; Nakashima K; Koshida K; Nakashima T; Miyazaki K; Namiki M
Anticancer Res; 2015 Sep; 35(9):5031-6. PubMed ID: 26254404
[TBL] [Abstract][Full Text] [Related]
14. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
[TBL] [Abstract][Full Text] [Related]
15. Could Magnetic Resonance Imaging Help to Identify the Presence of Prostate Cancer Before Initial Biopsy? The Development of Nomogram Predicting the Outcomes of Prostate Biopsy in the Chinese Population.
Fang D; Zhao C; Ren D; Yu W; Wang R; Wang H; Li X; Yin W; Yu X; Yang K; Liu P; Shan G; Li S; He Q; Wang X; Xin Z; Zhou L
Ann Surg Oncol; 2016 Dec; 23(13):4284-4292. PubMed ID: 27464612
[TBL] [Abstract][Full Text] [Related]
16. Prostate volume predicts high grade prostate cancer both in digital rectal examination negative (ct1c) and positive (≥ct2) patients.
Yilmaz H; Ustuner M; Ciftci S; Yavuz U; Ozkan TA; Dillioglugil O
Int Braz J Urol; 2014; 40(5):613-9. PubMed ID: 25498272
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen velocity (PSAV) and PSAV per initial volume (PSAVD) for early detection of prostate cancer in Chinese men.
Zheng XY; Zhang P; Xie LP; You QH; Cai BS; Qin J
Asian Pac J Cancer Prev; 2012; 13(11):5529-33. PubMed ID: 23317212
[TBL] [Abstract][Full Text] [Related]
18. Role of
Jiménez Londoño GA; García Vicente AM; Amo-Salas M; Fúnez Mayorga F; López Guerrero MA; Talavera Rubio MP; Gutierrez Martin P; González García B; de la Torre Pérez JA; Soriano Castrejón ÁM
Rev Esp Med Nucl Imagen Mol; 2017; 36(4):241-246. PubMed ID: 28330596
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of the international prostate symptom score for positive prostate needle biopsy in the low-intermediate prostate-specific antigen range.
Kefi A; Irer B; Ozdemir I; Tuna B; Goktay Y; Yorukoğlu K; Esen A
Urol Int; 2005; 75(3):222-6. PubMed ID: 16215309
[TBL] [Abstract][Full Text] [Related]
20. Clinical Significance of Proliferative Inflammatory Atrophy in Negative Prostatic Biopsies.
Servian P; Celma A; Planas J; Placer J; de Torres IM; Morote J
Prostate; 2016 Dec; 76(16):1501-1506. PubMed ID: 27404228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
